Thomas Devlin, MD
Neurology · Chattanooga, TNNPI 1891723284
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,360 of the $19,155 with a category attached, or 75.0%. Medtronic accounts for 82.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $12,663 and has fallen 98.2% since, to $227 in 2025.
Across 64 payments — averaging $299.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Genentech, Inc.$771
- Neurasignal Inc.$700
- Viz.ai, Inc.$619
- Neural Analytics, Inc.$189
- Microtransponder, Inc.$187
- plus $810 from 13 others
Across 94 payments — averaging $2912.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viz.ai, Inc.$192K
- Daiichi Sankyo Inc.$29K
- Sunovion Pharmaceuticals Inc.$23K
- Medtronic$20K
- Novocure Inc.$10K
What the payments were for
- Speaking & faculty fees$14,36075%
- Travel & lodging$2,02611%
- Food & beverage$2,76914%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(3 entities) | 22 | $15,879 |
| Genentech, Inc. | 3 | $771 |
| Neurasignal Inc. | 1 | $700 |
| Viz.ai, Inc. | 8 | $619 |
| Neural Analytics, Inc. | 5 | $189 |
| Microtransponder, Inc. | 1 | $187 |
| Siemens Medical Solutions USA, Inc. | 2 | $170 |
| AstraZeneca | 1 | $125 |
| CSL Behring | 1 | $99 |
| Johnson & Johnson(2 entities) | 4 | $96 |
| Genentech USA, Inc. | 2 | $87 |
| Pfizer | 4 | $62 |
| UCB, Inc. | 4 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| AbbVie | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| Abbott | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solitaire$3,710
- Pipeline$3,108
- Viz.AI LVO$379
- Reveal LINQ$174
- ANDEXXA$125
- CorPath Imaging System$110
How this compares
$19,155 in reported general payments places this provider in the 75th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 13 | $241 |
| Levetiracetam | 12 | $130 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $115 |
| Clonazepam | 20 | $30 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chattanooga
- David RankineChattanooga$167K
- Tareck KadrieChattanooga$150K
- Yuchun HanChattanooga$50K
- Chelsea ShugarsChattanooga$47K
- Jake McKayChattanooga$46K
- Berneet KaurChattanooga$27K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- David BrandesKnoxville$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.